Option chain shows key data for Orchestra BioMed Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Orchestra BioMed Hldgs.

Orchestra BioMed Hldgs (NASDAQ:OBIO) Stock, Option Chain

Orchestra BioMed Hldgs

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Biotech

Earnings

News

Markets

Analyst Ratings

Trading Ideas

General

ALKS

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) shares ended the last trading session 7.3% higher at $6.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock&#39;s 12.8% gain over the past four weeks.

Orchestra BioMed Holdings, Inc. Stock Jumps 7.3%: Will It Continue to Soar?

Short Ideas

Health Care

Small Cap

Pre-Market Outlook

CRNX

NXGN

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Top 4 Health Care Stocks That Should Keep You Up At Night

Penny Stocks

Intraday Update

Movers

AGRI

ASST

ATRA

AXLA

AZUL

BGNE

BJDX

BRDS

CATC

CLDI

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CSPI

CZOO

DTOC

EBET

EHTH

ELUT

EVAX

FRTX

GRRR

HAIN

HSTO

IBRX

ICCM

LIFW

MKUL

NMRA

NVOS

RNAZ

SEEL

SPRY

SWIN

Gainers

MSP Recovery, Inc.  (NASDAQ: LIFW) shares jumped 104.5% to $0.1916.

Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Orchestra BioMed Holdings Inc

"Alarum's fourth quarter 2024 revenues are estimated at $7.5 million ±3% and Adjusted EBITDA for the fourth quarter 2024 is expected to range from $1.3 million to $1.7 million."

Guidance

ALAR

Alarum Technologies Expects Q4 Revenue Of $7.5M ±3% Vs $7.48M Est

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) with a Buy and lowers the price target from $8 to $5.

Price Target

CARM

HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $5

WIIM

ELAB

Elevai Labs shares are trading lower after the company announced a 1-for-200 reverse stock split.

SNOW

Snowflake shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform.

UXIN

Uxin shares are trading higher after the company reported Q2 sales of $70.85 million, up from $48.80 million year-over-year.

Macy's shares are trading lower after the company delayed its Q3 earnings release and conference call, citing an issue related to delivery expenses in one of its accrual accounts, prompting an independent investigation.

BBWI

Bath & Body Works shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its 2024 guidance.

Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $325 to $385.

CRWD

Rosenblatt Maintains Buy on CrowdStrike Holdings, Raises Price Target to $385

The study is evaluating the safety, tolerability, efficacy, pharmacokinetics, and biomarkers of orally administered PL8177 in adult patients with active ulcerative colitis.

Palatin Technologies Has Completed Enrollment In Its Phase 2 Study Of PL8177 For Ulcerative Colitis, The Last Patient Visit Is Expected To Occur In Q1 Of 2025, With Topline Data Expected Shortly Thereafter

HC Wainwright &amp; Co. analyst Mitchell Kapoor initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell rating and announces Price Target of $80.

Initiation

SRPT

HC Wainwright & Co. Initiates Coverage On Sarepta Therapeutics with Sell Rating, Announces Price Target of $80

Cognition Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical-stage company developing drugs to treat neurodegenerative disorders, provided an update on a biomarker(1) analysis from the Phase 2 'SHINE' study in mild-to-moderate Alzheimer's disease. This new analysis focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau217(2) . Several blood-based measures of Alzheimer's disease biology were identified that were normalized in CT1812-treated participants compared to the placebo-treated participants. These biomarker changes occurred in concert with a 95% slowing of cognitive decline as measured by ADAS-Cog11 in the same patients. These data provide further evidence that CT1812 may be preserving cognitive function and slowing disease progression by protecting key neurological system. &nbsp;

CGTX

Cognition Therapeutics Announced 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer's Disease Biology

Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.05 by 300 percent. The company reported quarterly sales of $7.194 million which beat the analyst consensus estimate of $7.000 million by 2.77 percent. This is a 6.58 percent increase over sales of $6.750 million the same period last year.

Earnings Beats

Alarum Technologies Q3 2024 Adj. EPS $0.20 Beats $0.05 Estimate, Sales $7.194M Beat $7.000M Estimate

BHVN

Biohaven Says In RESILIENT SMA Study, Taldefgrobep Alfa Showed Clinically Meaningful Improvements In Motor Function At All Timepoints On The Motor Function Measurement-32 Scale, But The Treatment Arm Did Not Statistically Separate On The Primary Outcome At Week 48 Compared To The Placebo+Standard Of Care Group

Contracts

SRM Entertainment Announces Order From An Orlando Theme Park For Its Misting Fans; Initial Order Of $820K For US Theme Parks And $85K For International Parks

AVXL

Anavex Life Sciences Announces Acceptance Of Peer-Reviewed Manuscript Titled 'Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial' In A Reference Alzheimer's Disease Journal

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares are trading higher premarket on Monday after the company successfully completed its 56th Electron mission and finalized a&nbsp;$23.9 million&nbsp;award from the U.S. Department of Commerce.
The company deployed five satellites into Low Earth Orbit for French IoT constellation operator Kinéis.
Rocket Lab&#8217;s &#8220;Ice AIS Baby&#8221; mission successfully launched from New Zealand on November 25, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42156903/rocket-lab-successfully-launches-two-missions-in-less-than-24-hours" rel="noreferrer noopener">deploying five satellites into a 643 km orbit.</a>
The company set a record for its fastest turnaround, completing the launch just 21 hours and 55 minutes after another mission in Virginia.
This marks Rocket Lab&#8217;s 14th mission of 2024 and its 56th overall, bringing its total satellites launched to 203.
Rocket Lab founder and CEO Sir Peter Beck said, &#8220;Two successful launches less than 24 hours apart from pads in different hemispheres. That&#8217;s unprecedented capability in the small launch market and one we&#8217;re immensely proud to deliver at Rocket Lab.&#8221;
Kinéis CEO Alexandre Tisserant, added, &#8221;With 15 Kinéis satellites now in orbit, we&#8217;re one step closer to the full deployment of our dedicated IoT constellation for transmitting data in near-real time, anywhere on the globe.&#8221;
Apart from this, in a seperate release, Rocket Lab disclosed that it finalized&nbsp;a $23.9 million award from the U.S. Department of Commerce to expand its compound semiconductor<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42160043/rocket-lab-signs-23-9m-chips-incentives-award-to-boost-semiconductor-manufacturing" rel="noreferrer noopener"> manufacturing in Albuquerque, New Mexico</a>.
These semiconductors are critical for space-grade solar cells and optoelectronic products essential to national security and commercial applications.
This month, the company also announced a multi-launch agreement with a confidential customer and was awarded a&nbsp;defense contract <a target="_blank" href="https://www.benzinga.com/news/contracts/24/11/41941068/rocket-lab-stock-is-blasting-off-wednesday-whats-going-on" rel="noreferrer noopener">worth up to $8 million</a>.
Investors can gain exposure to the stock via&nbsp;Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>) and&nbsp;SPDR S&amp;P Kensho Final Frontiers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROKT#NYSE">ROKT</a>).
Price Action: RKLB shares are up 7.7% at $25.05 premarket at the last check Monday.
Photo via Company
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin" target="_blank" rel="noreferrer noopener">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Equities

Mid Cap

RKLB

ROKT

Why Is Rocket Lab USA Stock Surging Today?

Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). Nex-z is an in vivo&nbsp;CRISPR-based investigational&nbsp;therapy designed as a single-dose treatment to inactivate the&nbsp;TTR&nbsp;gene and thereby prevent the production of TTR protein for the treatment of ATTR amyloidosis. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron.
"This RMAT designation underscores the transformative potential of nex-z, our investigational in vivo CRISPR-based gene editing therapy for those living with hereditary ATTR amyloidosis with polyneuropathy," said Intellia President and Chief Executive Officer John Leonard, M.D. "It was granted following the FDA's review of our compelling interim Phase 1 data that indicated our one-time treatment led to rapid, deep and durable TTR reduction, which is expected to halt and potentially reverse the disease. We look forward to working closely with the FDA to bring this potential paradigm-shifting therapy to patients as quickly as possible."
The RMAT designation was established under the 21st Century Cures Act to expedite the development and review of promising therapeutic candidates, including genetic therapies, that are intended to treat, modify, reverse or cure a serious or life-threatening disease. RMAT designation includes benefits, such as early interactions with the FDA, including discussions on surrogate or intermediate endpoints that could potentially support accelerated approval and satisfy post-approval requirements, and potential priority review of a product's biologics license application (BLA).
This RMAT designation is the third special regulatory designation received by Intellia for nex-z. Nex-z was also granted Orphan Drug Designation by the U.S. FDA and European Union Orphan Drug Designation by the European Commission.
About nexiguran ziclumeran (nex-z, also known as NTLA-2001) Based on Nobel Prize-winning CRISPR/Cas9 technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate the&nbsp;TTR&nbsp;gene that encodes for the transthyretin (TTR) protein. Interim Phase 1 clinical data showed the administration of nex-z led to consistent, deep and long-lasting TTR reduction. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization&nbsp;collaboration&nbsp;with Regeneron.

Government

Regulations

NTLA

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Morgan Stanley analyst Toni Kaplan upgrades KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) from Equal-Weight to Overweight and announces $30 price target.

Upgrades

Morgan Stanley Upgrades KinderCare Learning to Overweight, Announces $30 Price Target

Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>, "Cassava", the "Company"))), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer's disease (AD) dementia, today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints. The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo. Simufilam continued to demonstrate an overall favorable safety profile. The Company will hold a webcast today at 8 AM ET.
"The results are disappointing for patients and their families who are living with this disease and physicians who have been looking for novel treatment options. We took careful measures to enroll patients with mild-to-moderate AD. Despite that, the loss of cognition in the placebo group was less pronounced than was previously reported in other placebo-controlled studies in AD. We are working to understand this better," said Rick Barry, President and Chief Executive Officer. "A result like this has implications on our second Phase 3 trial,&nbsp;ReFocus-ALZ. We have made the difficult decision to discontinue ReFocus-ALZ, given the nature of today's reported results. The complete 52-week dataset will be available from the study along with a large portion of 76-week data. We intend to report detailed analyses of both studies in the future. We will also be discontinuing the Open Label Extension study."
Mr. Barry continued, "We have a special gratitude for the patients and their families and caregivers who participated in our clinical program for AD. We are also immensely grateful to our employees, study investigators and site coordinators, as well as our other partners, for their commitment to this program. We hope the information we have gathered can ultimately be used to benefit ongoing research in AD."
The table below provides a high-level summary of the co-primary endpoints data. Topline analysis of the mild and moderate sub-groups, likewise, did not demonstrate statistical significance at week 52.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Co-Primary Endpoint Data&#x2A;</td>
<td>Simufilam 100 mg BID N= 403</td>
<td>Placebo BID N=401</td>
<td>Delta</td>
<td>P-value</td>
</tr>
<tr>
<td colspan="5">Co-Primary Endpoints LS means change from baseline to the end of the double-blind treatment period</td>
</tr>
<tr>
<td>ADAS-COG12 (SE)</td>
<td>2.8 ( 0.36)</td>
<td>3.2 ( 0.36)</td>
<td>-0.39 ( 0.50)</td>
<td>P=0.43</td>
</tr>
<tr>
<td>ADCS-ADL (SE)</td>
<td>-3.3 ( 0.44)</td>
<td>-3.8 ( 0.44)</td>
<td>0.51 ( 0.61)</td>
<td>P=0.40</td>
</tr>
<tr>
<td colspan="5">&#x2A;Based on the intent-to-treat population BID = twice daily ADAS-COG12 = The Alzheimer's Disease Assessment Scale – Cognitive Subscale (a lower number represents less cognitive impairment) ADCS-ADL = Alzheimer's Disease Cooperative Study – Activities of Daily Living (a higher number represents less functional impairment)</td>
</tr>
</tbody>
</table>
</figure>
The table below provides a high-level summary of the patient demographic and safety data. Simufilam continued to demonstrate an overall favorable safety profile.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Metrics for Simufilam and Placebo</td>
<td>Simufilam 100 mg BID</td>
<td>Placebo BID</td>
</tr>
<tr>
<td colspan="3">Baseline&#x2A;</td>
</tr>
<tr>
<td>Age, mean (SD), in years</td>
<td>73.7 7.9</td>
<td>74.3 7.6</td>
</tr>
<tr>
<td>Sex, n (%) female</td>
<td>225 (55.8%)</td>
<td>222 (55.4%)</td>
</tr>
<tr>
<td>MMSE Score (No.%,)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>21-27</td>
<td>244 (60.5%)</td>
<td>250 (62.3%)</td>
</tr>
<tr>
<td>16-20</td>
<td>155 (38.5%)</td>
<td>146 (36.4%)</td>
</tr>
<tr>
<td>Race/Ethnicity</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>White</td>
<td>366 (90.8%)</td>
<td>376 (93.8%)</td>
</tr>
<tr>
<td>Black</td>
<td>20 (5.0%)</td>
<td>18 (4.5%)</td>
</tr>
<tr>
<td>Asian</td>
<td>8 (2.0%)</td>
<td>2 (0.5%)</td>
</tr>
<tr>
<td>Other</td>
<td>9 (2.2%)</td>
<td>5 (1.0%)</td>
</tr>
<tr>
<td colspan="3">Safety&#x2A;&#x2A;</td>
</tr>
<tr>
<td>Any Adverse Event (AE)</td>
<td>284 (71.2%)</td>
<td>269 (67.6%)</td>
</tr>
<tr>
<td>Serious AEs</td>
<td>52 (13.0%)</td>
<td>36 (9.0%)</td>
</tr>
<tr>
<td>Death</td>
<td>1 (0.3%)</td>
<td>3 (0.8%)</td>
</tr>
<tr>
<td>AEs leading to discontinuation from the study</td>
<td>26 (6.5%)</td>
<td>17 (4.3%)</td>
</tr>
<tr>
<td>Most Frequent AEs</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>1: COVID-19</td>
<td>32 (8.0%)</td>
<td>36 (9.0%)</td>
</tr>
<tr>
<td>2: Urinary Tract Infection</td>
<td>31 (7.8%)</td>
<td>29 (7.3%)</td>
</tr>
<tr>
<td>3: Fall</td>
<td>30 (7.5%)</td>
<td>30 (7.5%)</td>
</tr>
<tr>
<td>4: Dizziness</td>
<td>21 (5.3%)</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>5: Headache</td>
<td>18 (4.5%)</td>
<td>11 (2.8%)</td>
</tr>
<tr>
<td colspan="3">&#x2A;Based on the intent-to-treat population &#x2A;&#x2A;Based on the safety population BID = twice daily AD = Alzheimer's disease MMSE = Mini-Mental State Examination</td>
</tr>
</tbody>
</table>
</figure>
 Cassava will continue to review all of the data and evaluate next steps. We plan to share the detailed results at a future medical meeting.
Eric Schoen, Chief Financial Officer at Cassava commented, "We remain focused on the interests of Cassava shareholders and are committed to enhancing shareholder value. Cassava is well-capitalized with approximately $149.0 million in cash and cash equivalents as of the end of the third quarter of 2024."

SAVA

Cassava Sciences Halts Alzheimer's Drug Trials After Phase 3 Results

Are you tired of the endless political drama? Maybe you're feeling like it's time for a real change, far from all the noise. How about this – a move to an idyllic Italian village where homes cost as little as one dollar? It sounds almost too good to be true, but Ollolai, a charming spot in Sardinia, Italy, is doing just that. They're welcoming frustrated Americans with open arms, offering a chance to swap out the tension of modern politics for the simple pleasures of small-town Italian life.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
This picturesque village has seen its population shrink drastically over the past decades. To breathe new life into the community, the local authorities devised a bold idea: sell abandoned, rundown homes for a mere €1 or $1. However, these homes need some love and renovation. For anyone willing to work, this is <a href="https://www.benzinga.com/markets/24/10/41149295/real-estate-in-italy-is-a-goldmine-for-investors-california-resident-snags-6-bedroom-2-kitchen-home">an amazing opportunity</a> to build a dream European escape from the ground up.
With its cobbled streets, historic stone houses and an air of tranquillity, Ollolai is a <a href="https://www.benzinga.com/news/24/01/36759767/you-might-be-eligible-to-buy-a-house-in-croatia-for-13-cents">hidden gem</a> just waiting for people to discover its charm and immerse in a different way of life – one where neighbors know each other, the air is clean and the food comes straight from local farms. It's a chance to live slowly and meaningfully, to enjoy simple pleasures like a morning espresso on a sunny terrace or an evening stroll with views of the rolling hills.
Trending: Invest in $20+ trillion home equity market today across cities like Austin, Miami, and Los Angeles through a <a href="https://www.benzinga.com/money/nada-cityfunds">unique 5-year term fund targeting a 14-20% IRR with minimums as low as $2,500</a>
<h2 class="wp-block-heading">Why Now?</h2>
Although the village has been selling <a href="https://www.benzinga.com/real-estate/24/05/39028524/a-look-at-japans-reverse-housing-crisis-where-millions-of-homes-sit-vacant">abandoned houses</a> for years, the push to attract American buyers has intensified in the wake of recent election results in the United States. Feeling disillusioned by the political situation? Ollolai's mayor, Francesco Columbu, told CNN that Americans are the perfect fit for the village's revival. To sweeten the deal, the village offers a fast-track process specifically for U.S. buyers, making securing your slice of Italian paradise easier than ever.
Not only are €1 houses available, but there are also move-in-ready homes for those who prefer a simpler transition. Prices for these homes are more substantial, reaching up to €100,000, but they come with the benefit of being ready for immediate living – no renovation required.
See Also: Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a>
<h2 class="wp-block-heading">What to Expect in Ollolai</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Ollolai, Italy: Hundreds of abandoned homes selling for just one euro. The stone-built dwellings need major renovations. Reporter <a href="https://twitter.com/hughwhitfeld?ref_src=twsrc%5Etfw">@HughWhitfeld</a>​. Cameraman @7_Cannon. <a href="https://twitter.com/hashtag/Ollolai?src=hash&amp;ref_src=twsrc%5Etfw">#Ollolai</a> <a href="https://twitter.com/hashtag/7News?src=hash&amp;ref_src=twsrc%5Etfw">#7News</a> <a href="https://t.co/eHGdGwYGHl">pic.twitter.com/eHGdGwYGHl</a>
&mdash; 7NEWS Sydney (@7NewsSydney) <a href="https://twitter.com/7NewsSydney/status/973892751317233665?ref_src=twsrc%5Etfw">March 14, 2018</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Life in Ollolai is peaceful and connected to nature. The village is located in a largely untouched region, offering clear air, scenic landscapes and a chance to unplug. Per CNN, many of the houses available for sale are old farmers' and shepherds' dwellings made of local granite, giving them a rustic charm that's hard to find anywhere else. Some are even fully furnished, with modern amenities while retaining their traditional style.
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

'Start Building Your European Escape' – Italian Village Offers $1 Homes For Americans Frustrated By Election Results

Orchestra BioMed Holdings (OBIO) has provided an update. Orchestra BioMed Holdings, Inc. has strengthened its corporate governance by appointing th...

Orchestra BioMed Bolsters Board with Strategic Appointment

Keay Nakae, an analyst from Chardan Capital, reiterated the Buy rating on Orchestra BioMed Holdings (OBIO – Research Report). The associated price ...

Buy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Developments

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Orchestra BioMed Hldgs (NASDAQ:<a href="https://investorplace.com/stock-quotes/obio-stock-quote/">OBIO</a>) just reported results for the second quarter of 2024.<ul><li>Orchestra BioMed Hldgs reported earnings per share of -45 cents. This was below the analyst estimate for EPS of -39 cents.</li><li>The company reported revenue of $778,000.</li><li>This was 3.73% better than the analyst estimate for revenue of $750,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/obio-stock-earnings-orchestra-biomed-hldgs-for-q2-of-2024/">OBIO Stock Earnings: Orchestra BioMed Hldgs Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OBIO Stock Earnings: Orchestra BioMed Hldgs Misses EPS, Beats Revenue for Q2 2024

Piper Sandler Remains a Buy on Orchestra BioMed Holdings (OBIO)

Orchestra BioMed reports Q2 results

Warning: OBIO is at high risk of performing badly

Reports Q3 revenue $987,000, consensus $710,000. "The Orchestra BioMed (OBIO) team is focused on execution of the BACKBEAT global pivotal study alo...

Orchestra BioMed reports Q EPS (41c), consensus (43c)

Orchestra Biomed Holdings, Inc. ( ($OBIO) ) has released its Q3 earnings. Here is a breakdown of the information Orchestra Biomed Holdings, Inc. pr...

Orchestra Biomed Reports Q3 2024 Financial Results

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Orchestra BioMed Holdings (OBIO – Research Report) today and set a price target of $2...

Orchestra BioMed Holdings: Strategic Financial Developments and Clinical Progress Justify Buy Rating

Orchestra BioMed GAAP EPS of -$0.41, revenue of $0.99M

Press Releases

Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

Management

Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances

Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed to Participate in Jefferies London Healthcare Conference

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Comments

Orchestra BioMed Hldgs

Orchestra BioMed Hldgs (OBIO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga